Fengyuan Pharmaceutical Industry: Obtained registration certificate for Compound Sodium Acetate Ringer Injection

Fengyuan Pharmaceutical announced that it has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the compound sodium acetate Ringer's injection and the compound sodium acetate Ringer's injection. The validity period of the drug approval numbers are both until February 24, 2031. This drug is used for the supplementation of extracellular fluid and correction of metabolic acidosis when the circulating blood volume and interstitial fluid are reduced. Obtaining the certificate will enrich the company's product line, optimize its structure, and enhance market competitiveness, but there are uncertainties in drug production and sales. Investors are reminded to pay attention to the risks.